ApoA-I-Directed Therapies for the Management of Atherosclerosis

Current Atherosclerosis Reports
John S Millar, Marina Cuchel

Abstract

Several recent reports have raised doubts about the atheroprotective role of high-density lipoprotein cholesterol (HDL-C). Nevertheless, a substantial body of work supports the validity of pharmacological interventions able to enhance HDL function, as opposed to raising HDL-C levels per se. In this article, we briefly review the development of pharmacological interventions that target apoA-I and HDL function as a means of reducing atherosclerotic risk: small molecule pharmaceuticals, small HDL mimetic peptides, and infusion of apoA-I-containing particles.

References

May 8, 2002·The Journal of Clinical Investigation·Jay D HortonMichael S Brown
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Erik G LundCarl P Sparrow
Aug 23, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Ryan E MooreDaniel J Rader
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Mar 7, 2006·Journal of the American College of Cardiology·Stephen J NichollsSteven E Nissen
Mar 28, 2007·JAMA : the Journal of the American Medical Association·Jean-Claude TardifUNKNOWN Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jan 16, 2009·Journal of Lipid Research·Frank M SacksH Bryan Brewer
Jun 2, 2010·Journal of the American College of Cardiology·Dana BaileyJacques Genest
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Nov 18, 2011·The Journal of Clinical Endocrinology and Metabolism·Christiane L HaaseRuth Frikke-Schmidt
Dec 23, 2011·Atherosclerosis·Laura CalabresiGuido Franceschini
Oct 25, 2012·Thrombosis and Haemostasis·Chiara GiannarelliJ J Badimon
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Oct 15, 2013·Journal of Clinical Pharmacology·Rachael EastonCharles Shear
Nov 20, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sarah PicaudPanagis Filippakopoulos
Jan 7, 2014·PloS One·Kevin G McLurePeter R Young

❮ Previous
Next ❯

Citations

Nov 11, 2017·Arteriosclerosis, Thrombosis, and Vascular Biology·Bradley K WackerDavid A Dichek
Jun 1, 2018·Current Medicinal Chemistry·Angela PirilloGiuseppe Danilo Norata
May 24, 2016·Current Opinion in Lipidology·Nicholas Brownell, Anand Rohatgi
Feb 7, 2018·Frontiers in Pharmacology·Nicholas J WoudbergMiguel A Frias
Sep 27, 2019·Pharmacological Reviews·Dongdong WangAtanas G Atanasov
Oct 13, 2021·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Ilaria ZanottiMarina Cuchel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

JAMA : the Journal of the American Medical Association
Inder M SinghBenjamin J Ansell
Handbook of Experimental Pharmacology
R M StoekenbroekG Kees Hovingh
Current Opinion in Endocrinology, Diabetes, and Obesity
Scott M Gordon, William S Davidson
© 2021 Meta ULC. All rights reserved